Venetoclax

Venetoclax works by targeting the BCL-2A protein that works to inhibit apoptosis (cell death). The gene was initially identified in a B cell lymphoma, from which it got its name. geneA stretch of DNA that leads to the production of an RNA. The RNA is produced during the process of transcription. This RNA can be used to guide the formation of a protein via translation or can be used directly in the cell., which is responsible for the inhibition of apoptosisAlso called programmed cell death. Apoptosis is a natural process that occurs throughout the lives of almost all animals and plants. The death of the cells is a carefully controlled process that does not generate any inflammation..  In addition, the BCL-2 gene is often associated with a LeukemiaA cancer affecting the cells that develop into white or red blood cells. Both of these cell types originate from stem cells in bone marrow. Red blood cells function to carry oxygen to our tissues and the white cells (leukocytes) are part of our immune system. The cancerous cells often accumulate in the blood. cell's resistance to chemotherapyTreatment of cancer patients with anticancer drugs. Commonly called 'chemo'. These drugs work by attacking cell growth or division. Often these agents are used in combination to take advantage of their different modes of attack on cell division..  Venetoclax looks to bring on apoptosis of cancerous cells by mitigating the effect of this BCL-2 gene.1